WO2003083072A3 - In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states - Google Patents

In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states Download PDF

Info

Publication number
WO2003083072A3
WO2003083072A3 PCT/US2003/009497 US0309497W WO03083072A3 WO 2003083072 A3 WO2003083072 A3 WO 2003083072A3 US 0309497 W US0309497 W US 0309497W WO 03083072 A3 WO03083072 A3 WO 03083072A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
vivo method
determining
animal
animal models
Prior art date
Application number
PCT/US2003/009497
Other languages
French (fr)
Other versions
WO2003083072A2 (en
Inventor
Jill Giles-Komar
Kim Staquet
Original Assignee
Centocor Inc
Jill Giles-Komar
Kim Staquet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Jill Giles-Komar, Kim Staquet filed Critical Centocor Inc
Priority to AU2003226100A priority Critical patent/AU2003226100A1/en
Publication of WO2003083072A2 publication Critical patent/WO2003083072A2/en
Publication of WO2003083072A3 publication Critical patent/WO2003083072A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

An in vivo method for screening hybridomas for the production of monoclonal antibodies having a desired biological activity in an animal model which comprises: injecting subcutaneously into a test animal, monoclonal antibody producing hybridoma cells in combination with a basement membrane protein composition, allowing the monoclonal antibody to be released into the circulatory system of the animal, and measuring the efficacy of the monoclonal antibody in the animal.
PCT/US2003/009497 2002-03-27 2003-03-27 In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states WO2003083072A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003226100A AU2003226100A1 (en) 2002-03-27 2003-03-27 In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37041802P 2002-03-27 2002-03-27
US60/370,418 2002-03-27

Publications (2)

Publication Number Publication Date
WO2003083072A2 WO2003083072A2 (en) 2003-10-09
WO2003083072A3 true WO2003083072A3 (en) 2004-07-01

Family

ID=28675591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009497 WO2003083072A2 (en) 2002-03-27 2003-03-27 In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states

Country Status (2)

Country Link
AU (1) AU2003226100A1 (en)
WO (1) WO2003083072A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735298A1 (en) * 2008-09-22 2010-03-25 F. Hoffmann-La Roche Ag Method for determining the anti-tumor efficacy of monoclonal antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287558B1 (en) * 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287558B1 (en) * 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAVELKOUL H.F. ET AL.: "Modulation of systemic cytokine levels by implantation of alginate encapsulated cells", J. IMMUNOL. METHODS, vol. 170, 1994, pages 185 - 196, XP002973281 *
THORSEN F. ET AL.: "Alginate-encapsulated producer cells: A potential new approach for the treatment of malignant brain tumors", CELL TRANSPLANT, vol. 9, 2000, pages 773 - 783, XP002973282 *

Also Published As

Publication number Publication date
AU2003226100A1 (en) 2003-10-13
AU2003226100A8 (en) 2003-10-13
WO2003083072A2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
WO2006002100A3 (en) Diagnostic and screening methods and kits associated with proteolytic activity
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
WO2008060777A3 (en) Elisa for vegf
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
WO2004012658A3 (en) Method and device for protein delivery into cells
WO2004041865A3 (en) Stabilized single domain antibodies
WO2007127936A3 (en) Methods and compositions for antibody therapy
EP2289944A3 (en) Bispecific antibody substituting for functional proteins
EP2604111A3 (en) Animal models and therapeutic molecules
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
WO2001036972A3 (en) Elisa for vegf
WO2005106494A3 (en) Monoclonal antibodies, hybridomas, improved method for determining the protein ptx3 and kit for said determination
NO2009012I1 (en) Humanized anti-human IL-6 receptor monoclonal antibody
Guo et al. Building a microphysiological skin model from induced pluripotent stem cells
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
WO2005007198A3 (en) Design of disease specific agents for diagnostics and therapeutics based on the protein isoform of vegf, her-2, psa
WO1999057306A3 (en) Method for diagnosing a vascular condition
ATE429449T1 (en) ANTI-FAS LIGAND ANTIBODIES AND TESTING METHOD USING THE SAME
WO2005115459A3 (en) Anti-viral activity of an anti-thymidine kinase monoclonal antibody
WO2003083072A3 (en) In vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of disease states
AU5352901A (en) Method for quantification of akt protein expression
WO2005012509A3 (en) Method for immunotherapy of tumors
WO2001069247A3 (en) Methods of making and using microarrays of anti-ligands for the analysis of protein expression in cells
EP1731032A4 (en) Nonhuman animals for antibody production, and methods and systems for producing antibodies using such animals
WO2001013714A3 (en) Prostatic cell line and animal model of a prostatic tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP